WHO grants prequalification to Sinovac's trivalent influenza vaccine
Published · Updated
What happened
The World Health Organization confirmed on November 4 that Beijing Sinovac Biotech's trivalent influenza vaccine, Anflu®, passed WHO prequalification. This is the first Chinese-produced influenza vaccine to enter the United Nations procurement list.
Why it matters
WHO prequalification allows the vaccine to be considered for procurement by UN agencies and by countries that use WHO PQ as a purchasing or registration benchmark. The change can affect near-term vaccine export opportunities, supplier competition in international flu immunization programs, and external recognition of Chinese vaccine quality systems.
The World Health Organization officially confirmed that Sinovac Biotech's trivalent influenza vaccine, Anflu®, passed WHO prequalification, making it the first domestically produced Chinese influenza vaccine added to the UN procurement list. The confirmation was reported within the past 24 hours and creates an immediate opening for participation in UN-system and other international tenders that rely on WHO PQ status. The development also serves as an external validation point for China's vaccine manufacturing and regulatory pathway in seasonal influenza products.
Watch for
UNICEF Supply Division tender documents or supplier roster updates naming Anflu on or after 2026-11-06 WHO prequalification database entry details for Anflu, including product status and listed presentation, on or after 2026-11-06 Sinovac Biotech disclosure of export orders, distribution agreements, or first UN-system procurement participation by 2026-11-09 China's National Medical Products Administration or Ministry of Commerce statement on support measures for WHO-PQ vaccine exports by 2026-11-09
Sources
- 疫苗与生物医药每日监测（2026-11-05） · vaccine.vip
Researched and written by AI from the sources listed, under published rules. How V³ Aware is made